相关实验视频

Updated: Jun 13, 2025

5/6 Nephrectomy Using Sharp Bipolectomy Via Midline Laparotomy in Rats

5/6 Nephrectomy Using Sharp Bipolectomy Via Midline Laparotomy in Rats

Published on: April 4, 2025

关于重症多中心卡斯特曼病的治疗策略的假设,包括连续脏替代疗法

Cătălin Constantinescu^1,2,3,4, David Kegyes⁴, Bogdan Tigu⁴

¹Department of Hematology, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania.

Journal of cellular and molecular medicine

|September 10, 2024

概括

卡斯特曼病 (CD) 的管理可以通过连续脏替代疗法 (CRRT) 改善. 在多中心性CD患者中,CRRT有效地去除IL-6,减轻严重症状和器官衰竭.

科学领域:

血液学血液学血液学
腎臟病學 (nephrology) 是一種醫學專業.
关键护理医学关键护理医学

背景情况:

卡斯特曼病 (CD) 是一种罕见的淋巴增殖性疾病,具有具有挑战性的诊断和有限的治疗选择.
多中心性CD (MCD) 呈现出严重的炎症反应,B型症状和全身并发症.
洲际蛋白-6 (IL-6) 是一种关键的细胞因子,涉及到MCD的发病和疾病活动.

研究的目的:

建议持续置换疗法 (CRRT) 作为重症多中心卡斯特曼病的管理策略.
探索CRRT在缓解细胞因子风暴和与MCD相关的全身并发症方面的潜力.

主要方法:

文献审查以收集CRRT对细胞因子清除的证据.
分析CRRT与MCD并发症相关的生理效应 (IL-6去除,肝素调节,减少).

主要成果:

CRRT能够从循环中去除IL-6和其他细胞因子,从而有可能减少炎症级联.
CRRT可以影响肝素水平,管理,并支持关键疾病中的器官功能.
有证据表明,在各种临床环境中,CRRT成功消除了细胞因子.

结论:

连续脏置换疗法 (CRRT) 显示为治疗或桥梁治疗严重多中心卡斯特曼病的承诺.
CRRT可以减轻细胞因子风暴,管理全身并发症,并改善MCD患者的治疗结果.
需要进一步的研究来确定CRRT在MCD治疗中的有效性.

关键词:

卡斯特曼病是什么?卡斯特曼病是什么?连续的代疗法是持续的代疗法重症监护病房的重症监护病房是一个重症监护病房.

更多相关视频

5/6th Nephrectomy in Combination with High Salt Diet and Nitric Oxide Synthase Inhibition to Induce Chronic Kidney Disease in the Lewis Rat

5/6th Nephrectomy in Combination with High Salt Diet and Nitric Oxide Synthase Inhibition to Induce Chronic Kidney Disease in the Lewis Rat

Published on: July 3, 2013

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies

Published on: April 12, 2017

相关概念视频

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...